FibroBiologics Inc. (FBLG) vs Longeveron Inc. (LGVN)

FibroBiologics Inc. and Longeveron Inc. are both Biotechnology companies. FibroBiologics Inc. and Longeveron Inc. are of similar size ($9.1M and $9.1M). FibroBiologics Inc. has the higher net margin (0.00% vs −1,977.6%) and the higher return on invested capital (−932.7% vs −4,549.0%). Across the 12 metrics below, FibroBiologics Inc. leads on 6 and Longeveron Inc. on 6.

Valuation

Metric FBLG LGVN Biotechnology median
P/E n/m n/m 7.88
P/S n/m 7.43 11.47
P/B 1.88 0.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 0.09 10.73
Earnings yield (373.38%) (352.31%) (28.84%)
Free cash flow yield (172.63%) (236.36%) (23.03%)

Profitability

Metric FBLG LGVN Biotechnology median
Gross margin — 69.76% 65.16%
Operating margin 0.00% (1,992.84%) 0.00%
Net margin 0.00% (1,977.59%) 0.00%
Free cash flow margin 0.00% (1,755.69%) 0.00%
Return on equity (660.08%) (203.61%) (57.72%)
Return on assets (166.14%) (145.64%) (49.22%)
Return on invested capital (932.71%) (4,549.04%) 0.00%

Growth

Metric FBLG LGVN Biotechnology median
Revenue growth (TTM) — (42.74%) 5.64%
EPS growth (last fiscal year) (23.53%) 50.76% —
Revenue growth, 5-year CAGR — (26.60%) 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric FBLG LGVN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.64 2.63 4.73
Net debt to EBITDA 0.31 0.20 0.96

Dividend

Metric FBLG LGVN Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric FBLG LGVN Biotechnology median
Market cap 9.06m 9.12m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack